Alessandra Narcisi
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 219 publications
Real-World Effectiveness and Safety of Bimekizumab for Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Study from the Italian Landscape HS (IL-HS).
Journal: Dermatology and therapy
Published: July 14, 2026
Real-world effectiveness of topical ruxolitinib in non-segmental vitiligo: repigmentation, mental health, and quality-of-life outcomes in an 860-patient multicentre study.
Journal: The British journal of dermatology
Published: May 16, 2026
Real-World Effectiveness and Safety of 12 Months of Tralokinumab in Patients with Atopic Dermatitis.
Real-World Effectiveness and Safety of 12 Months of Tralokinumab in Patients with Atopic Dermatitis.
Journal: Dermatology and therapy
Published: May 15, 2026
Comparative Effectiveness and Safety of Baricitinib and Ritlecitinib in Severe Alopecia Areata: A Real-World Monocentric Retrospective Study.
Journal: Dermatology and therapy
Published: May 05, 2026
Bullous Pemphigoid Disease Area Index Pruritus, Activity, and Damage During Biologic Therapy in Bullous Pemphigoid: An International Dual-Center Study.
Journal: The Journal of dermatology
Published: April 27, 2026
JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study.
Journal: Dermatology and therapy
Published: April 24, 2026
Dose Adjustment of JAK Inhibitors for the Management of Moderate-to-Severe Atopic Dermatitis: A Single-Centre Retrospective Study.
Journal: Medicina (Kaunas, Lithuania)
Published: April 13, 2026
Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter Study.
Journal: Clinical and experimental dermatology
Published: April 12, 2026
Baricitinib versus ritlecitinib for severe alopecia areata: A 24-week real-world study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: April 11, 2026
Beyond Psoriasis Area and Severity Index and Body Surface Area: An Italian Delphi Consensus on the Definition of Moderate Psoriasis.
Journal: Dermatology and therapy
Published: April 10, 2026
Tildrakizumab in the treatment of moderate-to-severe plaque psoriasis: expert insights from Italian real-world experience.
Journal: Expert opinion on biological therapy
Published: April 01, 2026
Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis).
Journal: Dermatology and therapy
Published: March 17, 2026
Last Updated: 09/26/2026